FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006180429> ?p ?o ?g. }

• W3006180429 endingPage "455" @default.
• W3006180429 startingPage "446" @default.
• W3006180429 abstract "Patients with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet been established. Pharmacological inhibition of MET signalling and aberrant angiogenesis has shown promising results in several preclinical models of Ewing sarcoma and osteosarcoma. We aimed to investigate the activity of cabozantinib, an inhibitor of MET and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma.We did a multicentre, single-arm, two-stage, phase 2 trial in patients with advanced Ewing sarcoma or osteosarcoma recruited from ten centres in the French Sarcoma Group. Key eligibility criteria were aged 12 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and documented disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1) before study entry. The number of previous lines of treatment was not limited. Patients received cabozantinib (adults 60 mg, children [<16 years] 40 mg/m2) orally once daily in 28-day cycles until disease progression, unacceptable toxicity, the investigator's decision to discontinue, or participant withdrawal. The primary endpoint for Ewing sarcoma was best objective response within 6 months of treatment onset; for osteosarcoma, a dual primary endpoint of 6-month objective response and 6-month non-progression was assessed. All enrolled patients who received at least one dose of cabozantinib were included in the safety analysis, and all participants who received at least one complete or two incomplete treatment cycles were included in the efficacy population. This study was registered with ClinicalTrials.gov, number NCT02243605.Between April 16, 2015, and July 12, 2018, 90 patients (45 with Ewing sarcoma 45 with osteosarcoma) were recruited to the study. Median follow-up was 31·3 months (95% CI 12·4-35·4) for patients with Ewing sarcoma and 31·1 months (24·4-31·7) for patients with osteosarcoma. 39 (87%) patients with Ewing sarcoma and 42 (93%) patients with osteosarcoma were assessable for efficacy after histological and radiological review. In patients with Ewing sarcoma, ten (26%; 95% CI 13-42) of 39 patients had an objective response (all partial responses) by 6 months; in patients with osteosarcoma, five (12%; 4-26) of 42 patients had an objective response (all partial responses) and 14 (33%; 20-50) had 6-month non-progression. The most common grade 3 or 4 adverse events were hypophosphataemia (five [11%] for Ewing sarcoma, three [7%] for osteosarcoma), aspartate aminotransferase increase (two [4%] for Ewing sarcoma, three [7%] for osteosarcoma), palmar-plantar syndrome (three [7%] for Ewing sarcoma, two [4%] for osteosarcoma), pneumothorax (one [2%] for Ewing sarcoma, four [9%] for osteosarcoma), and neutropenia (two [4%] for Ewing sarcoma, four [9%] for osteosarcoma). At least one serious adverse event was reported in 61 (68%) of 90 patients. No patients died from drug-related toxic effects.Cabozantinib has antitumor activity in patients with advanced Ewing sarcoma and osteosarcoma and was generally well tolerated. Cabozantinib could represent a new therapeutic option in this setting, and deserves further investigation.Institut Bergonié; French National Cancer Institute; Association pour la Recherche contre le Cancer." @default.
• W3006180429 created "2020-02-24" @default.
• W3006180429 creator A5003536346 @default.
• W3006180429 creator A5007096008 @default.
• W3006180429 creator A5019781329 @default.
• W3006180429 creator A5020672869 @default.
• W3006180429 creator A5027165899 @default.
• W3006180429 creator A5033320602 @default.
• W3006180429 creator A5042202815 @default.
• W3006180429 creator A5042760390 @default.
• W3006180429 creator A5044397434 @default.
• W3006180429 creator A5047589622 @default.
• W3006180429 creator A5051870782 @default.
• W3006180429 creator A5053409630 @default.
• W3006180429 creator A5057075276 @default.
• W3006180429 creator A5060949051 @default.
• W3006180429 creator A5062715691 @default.
• W3006180429 creator A5065856111 @default.
• W3006180429 creator A5069010161 @default.
• W3006180429 creator A5073782592 @default.
• W3006180429 creator A5074959994 @default.
• W3006180429 creator A5076354847 @default.
• W3006180429 creator A5080620486 @default.
• W3006180429 creator A5084836759 @default.
• W3006180429 date "2020-03-01" @default.
• W3006180429 modified "2023-10-12" @default.
• W3006180429 title "Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial" @default.
• W3006180429 cites W1534235733 @default.
• W3006180429 cites W1540759505 @default.
• W3006180429 cites W1715359867 @default.
• W3006180429 cites W2019607817 @default.
• W3006180429 cites W2022983661 @default.
• W3006180429 cites W2029409133 @default.
• W3006180429 cites W2047985610 @default.
• W3006180429 cites W2052907781 @default.
• W3006180429 cites W2055787036 @default.
• W3006180429 cites W2057195209 @default.
• W3006180429 cites W2075150872 @default.
• W3006180429 cites W2107172831 @default.
• W3006180429 cites W2108003570 @default.
• W3006180429 cites W2119104473 @default.
• W3006180429 cites W2122813583 @default.
• W3006180429 cites W2122891049 @default.
• W3006180429 cites W2128486176 @default.
• W3006180429 cites W2155263737 @default.
• W3006180429 cites W2157092733 @default.
• W3006180429 cites W2157539187 @default.
• W3006180429 cites W2282156262 @default.
• W3006180429 cites W2473766695 @default.
• W3006180429 cites W2601520864 @default.
• W3006180429 cites W2758151211 @default.
• W3006180429 cites W2805304375 @default.
• W3006180429 cites W2895615439 @default.
• W3006180429 cites W2901259053 @default.
• W3006180429 cites W2902920455 @default.
• W3006180429 cites W2925106048 @default.
• W3006180429 cites W2941090871 @default.
• W3006180429 cites W2944108527 @default.
• W3006180429 cites W4244970282 @default.
• W3006180429 cites W2329328181 @default.
• W3006180429 doi "https://doi.org/10.1016/s1470-2045(19)30825-3" @default.
• W3006180429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32078813" @default.
• W3006180429 hasPublicationYear "2020" @default.
• W3006180429 type Work @default.
• W3006180429 sameAs 3006180429 @default.
• W3006180429 citedByCount "171" @default.
• W3006180429 countsByYear W30061804292020 @default.
• W3006180429 countsByYear W30061804292021 @default.
• W3006180429 countsByYear W30061804292022 @default.
• W3006180429 countsByYear W30061804292023 @default.
• W3006180429 crossrefType "journal-article" @default.
• W3006180429 hasAuthorship W3006180429A5003536346 @default.
• W3006180429 hasAuthorship W3006180429A5007096008 @default.
• W3006180429 hasAuthorship W3006180429A5019781329 @default.
• W3006180429 hasAuthorship W3006180429A5020672869 @default.
• W3006180429 hasAuthorship W3006180429A5027165899 @default.
• W3006180429 hasAuthorship W3006180429A5033320602 @default.
• W3006180429 hasAuthorship W3006180429A5042202815 @default.
• W3006180429 hasAuthorship W3006180429A5042760390 @default.
• W3006180429 hasAuthorship W3006180429A5044397434 @default.
• W3006180429 hasAuthorship W3006180429A5047589622 @default.
• W3006180429 hasAuthorship W3006180429A5051870782 @default.
• W3006180429 hasAuthorship W3006180429A5053409630 @default.
• W3006180429 hasAuthorship W3006180429A5057075276 @default.
• W3006180429 hasAuthorship W3006180429A5060949051 @default.
• W3006180429 hasAuthorship W3006180429A5062715691 @default.
• W3006180429 hasAuthorship W3006180429A5065856111 @default.
• W3006180429 hasAuthorship W3006180429A5069010161 @default.
• W3006180429 hasAuthorship W3006180429A5073782592 @default.
• W3006180429 hasAuthorship W3006180429A5074959994 @default.
• W3006180429 hasAuthorship W3006180429A5076354847 @default.
• W3006180429 hasAuthorship W3006180429A5080620486 @default.
• W3006180429 hasAuthorship W3006180429A5084836759 @default.
• W3006180429 hasBestOaLocation W30061804291 @default.
• W3006180429 hasConcept C121608353 @default.
• W3006180429 hasConcept C126322002 @default.
• W3006180429 hasConcept C141071460 @default.
• W3006180429 hasConcept C142724271 @default.

• next